NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

COLO.B.DK

394.7

-0.58%↓

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

COLO.B.DK

394.7

-0.58%↓

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

COLO.B.DK

394.7

-0.58%↓

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

COLO.B.DK

394.7

-0.58%↓

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

NOVO.B.DK

272.65

+7.13%↑

GMAB.DK

1,689

+2.52%↑

COLO.B.DK

394.7

-0.58%↓

ZEAL.DK

299.4

+0.07%↑

AMBUB.DK

63.1

+2.69%↑

Kodu・Aktsiate loetelu・H Lundbeck A-S

H
H Lundbeck A-S

Suletud

42.86 2.68

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.72

Max

42.92

Põhinäitajad
By Trading Economics
Sissetulek	-1.7B -27M
Müük	-465M 5.8B
P/E Sektori keskmine	13.738 67.147
Aktsiakasum	0.94
Dividenditootlus	2.6
Kasumimarginaal	-0.464
Töötajad	5,039
EBITDA	130M 1.8B

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.60% 2.36%

Turustatistika
By TradingEconomics
Turukapital	3.2B 44B
Eelmine avamishind	40.18
Eelmine sulgemishind	42.86

H Lundbeck A-S Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 23:08 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 23:07 UTC

Tulu

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:20 UTC

Tulu

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. apr 2026, 23:22 UTC

Tulu

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. apr 2026, 22:52 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:33 UTC

Tulu

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. apr 2026, 22:05 UTC

Tulu

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 21:57 UTC

Tulu

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. apr 2026, 21:55 UTC

Tulu

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. apr 2026, 21:53 UTC

Tulu

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Võrdlus sarnastega

Hinnamuutus

H Lundbeck A-S Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.